- Home
- BRNS vs LSTA Comparison
BRNS vs LSTA Comparison
Compare BRNS & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BRNS | LSTA |
|---|---|---|
| Founded | 2016 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Misc Health and Biotechnology Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.1M | 28.9M |
| IPO Year | 2021 | 2000 |
Fundamental Metrics
Financial Performance| Metric | BRNS | LSTA |
|---|---|---|
| Price | $0.67 | $3.15 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $4.00 | ★ $15.00 |
| AVG Volume (30 Days) | 20.8K | ★ 48.7K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.42 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,283,868.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 56.90 |
| 52 Week Low | $0.51 | $1.81 |
| 52 Week High | $2.91 | $5.07 |
Technical Indicators
Market Signals| Indicator | BRNS | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 55.06 | 37.39 |
| Support Level | $0.66 | $2.75 |
| Resistance Level | $0.76 | $3.41 |
| Average True Range (ATR) | 0.06 | 0.14 |
| MACD | -0.00 | 0.05 |
| Stochastic Oscillator | 50.08 | 31.71 |
Price Performance
Historical ComparisonAbout BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.